Education
About Us
Working with TipRanks
Follow Us
Emil Kuriakose Insider Profile
4 Followers
Emil Kuriakose, CMO at Calithera Bio, holds 54.27K shares in Terns Pharmaceuticals (Ticker: TERN), holds 3.54K shares in Calithera Bio (Ticker: CALA). Most recently, Emil Kuriakose Sold ― shares of Terns Pharmaceuticals on Jan 06, 2025 for an estimated value of 25.59K.
Emil Kuriakose Calithera Bio (CALA)CMO
Calithera Bio (CALA)
CMO
Not Ranked
Emil Kuriakose has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CMO
Roles that Emil Kuriakose holds in companies
Most Profitable Insider Trade
The most profitable trade made by Emil Kuriakose
Emil Kuriakose's Trading History
Calithera Bio
Jan 25, 2023
―
Uninformative Sell
34.76
$88.47
Terns Pharmaceuticals
Jan 06, 2025
CMO
Informative Sell
25.59K
$189.40K
List of latest transactions for each holding click on a transaction to see Emil Kuriakose's performance on stock
You May Also Like
Emil Kuriakose insider profile FAQ
What is the percentage of profitable transactions made by Emil Kuriakose?
The percentage of profitable transactions made by Emil Kuriakose is ―.
What is the average return per transaction made by Emil Kuriakose?
The average return per transaction made by Emil Kuriakose is ―.
What stocks does Emil Kuriakose hold?
Emil Kuriakose holds: CALA, TERN stocks.
What was Emil Kuriakose’s latest transaction?
Emil Kuriakose latest transaction was an Informative Sell of $25.59K.
What was Emil Kuriakose's most profitable transaction?
Emil Kuriakose’s most profitable transaction was an Informative Sell of TERN stock on January 6, 2025. The return on the trade was 38.80%.
What is Emil Kuriakose's role in Calithera Bio?
Emil Kuriakose's role in Calithera Bio is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.